Get the Stockscreener App
7.13
2.33%
-0.17
After Hours:
7.11
-0.02
-0.28%
Ardelyx Inc stock is traded at $7.13, with a volume of 5.86M.
It is down -2.33% in the last 24 hours and up +20.03% over the past month.
Ardelyx Inc is a biopharmaceutical company developing and commercialize, first-in-class medicines that meet unmet medical needs. It has developed a platform that enabled the discovery of new biological mechanisms and pathways to develop potent and efficacious therapies that minimize the side effects and drug-drug interactions frequently encountered with traditional, systemically absorbed medicines. Its products Tenapanor, branded as IBSRELA, is used for the treatment of adults with IBS-C. Tenapanor, branded as XPHOZAH, is used to reduce serum phosphorus in adults with CKD on dialysis as add-on therapy in patients who have an inadequate response to phosphate binders or who are intolerant of any dose of phosphate binder therapy.
See More
Previous Close:
$7.30
Open:
$7.3
24h Volume:
5.86M
Relative Volume:
1.53
Market Cap:
$1.76B
Revenue:
$407.32M
Net Income/Loss:
$-61.60M
P/E Ratio:
-27.68
EPS:
-0.2576
Net Cash Flow:
$-43.98M
1W Performance:
+19.43%
1M Performance:
+20.03%
6M Performance:
+19.83%
1Y Performance:
+90.90%
1-Day Range:
$6.94
$7.425
1-Week Range:
$5.82
$7.43
52-Week Range:
$3.21
$8.40
Ardelyx Inc Stock (ARDX) Company Profile
Name
Ardelyx Inc
Sector
Industry
Phone
510-745-7047
Address
34175 ARDENWOOD BLVD., FREMONT, CA
Compare ARDX vs VRTX, REGN, ARGX, ALNY, ONC
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
ARDX
Ardelyx Inc
|
7.13 | 1.80B | 407.32M | -61.60M | -43.98M | -0.2576 |
VRTX
Vertex Pharmaceuticals Inc
|
424.36 | 109.34B | 12.32B | 4.34B | 3.19B | 16.86 |
REGN
Regeneron Pharmaceuticals Inc
|
702.27 | 74.35B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
794.70 | 50.44B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
301.11 | 39.78B | 3.71B | 313.75M | 465.38M | 2.2571 |
ONC
Beone Medicines Ltd Adr
|
297.49 | 33.02B | 5.36B | 287.73M | 924.18M | 2.5229 |
Ardelyx Inc Stock (ARDX) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Jan-09-26 | Upgrade | Piper Sandler | Neutral → Overweight |
| Sep-03-25 | Resumed | Raymond James | Strong Buy |
| Jun-18-25 | Resumed | H.C. Wainwright | Buy |
| May-02-25 | Downgrade | Raymond James | Strong Buy → Outperform |
| Mar-07-25 | Resumed | Ladenburg Thalmann | Buy |
| Mar-04-25 | Initiated | BTIG Research | Buy |
| Nov-11-24 | Downgrade | H.C. Wainwright | Buy → Neutral |
| Jul-02-24 | Downgrade | Piper Sandler | Overweight → Neutral |
| Apr-05-24 | Initiated | Leerink Partners | Outperform |
| Dec-18-23 | Initiated | Raymond James | Strong Buy |
| Sep-07-23 | Initiated | H.C. Wainwright | Buy |
| Aug-25-23 | Upgrade | Cantor Fitzgerald | Neutral → Overweight |
| Mar-03-23 | Upgrade | Wedbush | Neutral → Outperform |
| Nov-17-22 | Upgrade | Piper Sandler | Neutral → Overweight |
| May-06-22 | Downgrade | Cantor Fitzgerald | Overweight → Neutral |
| Dec-01-21 | Upgrade | Ladenburg Thalmann | Neutral → Buy |
| Oct-14-21 | Downgrade | Ladenburg Thalmann | Buy → Neutral |
| Jul-21-21 | Downgrade | Jefferies | Buy → Hold |
| Jul-20-21 | Downgrade | Piper Sandler | Overweight → Neutral |
| Jul-20-21 | Downgrade | Wedbush | Outperform → Neutral |
| Mar-23-21 | Initiated | Wedbush | Outperform |
| Jan-06-21 | Initiated | Cantor Fitzgerald | Overweight |
| Oct-20-20 | Resumed | Citigroup | Buy |
| Feb-18-20 | Resumed | Jefferies | Buy |
| Feb-12-20 | Initiated | Citigroup | Buy |
| Feb-10-20 | Initiated | Cowen | Outperform |
| Apr-08-19 | Initiated | Piper Jaffray | Overweight |
| Aug-24-18 | Initiated | Jefferies | Buy |
| Mar-19-18 | Resumed | Leerink Partners | Outperform |
| Nov-29-17 | Reiterated | Citigroup | Buy |
| Nov-22-17 | Reiterated | Ladenburg Thalmann | Buy |
| Oct-17-17 | Resumed | Leerink Partners | Outperform |
| Mar-31-16 | Initiated | Ladenburg Thalmann | Buy |
| Mar-09-16 | Initiated | Cantor Fitzgerald | Buy |
| Mar-03-16 | Initiated | Citigroup | Buy |
View All
Ardelyx Inc Stock (ARDX) Latest News
ARDX SEC FilingsArdelyx 10-K, 10-Q, 8-K Forms - Stock Titan
Ardelyx (NASDAQ:ARDX) Strengthens Amid Biotech Momentum - Kalkine Media
Earnings Update: Ardelyx, Inc. (NASDAQ:ARDX) Just Reported Its First-Quarter Results And Analysts Are Updating Their Forecasts - simplywall.st
Ardelyx reiterates 2026 guidance as IBSRELA targets $1B in 2029 while advancing ACCEL CIC Phase III enrollment by year-end - MSN
A Look At Ardelyx (ARDX) Valuation After Strong Q1 Results And Updated 2026 Guidance - simplywall.st
Analyst Estimates: Here's What Brokers Think Of Ardelyx, Inc. (NASDAQ:ARDX) After Its First-Quarter Report - Yahoo Finance
AIGH Capital Management LLC Purchases 951,500 Shares of Ardelyx, Inc. $ARDX - MarketBeat
Ardelyx Projects $1 Billion Revenue for Ibsrela by 2029 - HarianBasis.co
Ardelyx Earnings Call: Ibsrela Surge Fuels Bold Targets - TipRanks
Piper Sandler Maintains Ardelyx(ARDX.US) With Buy Rating, Maintains Target Price $16 - Moomoo
Ardelyx Posts Strong Q1 2026 Revenue, Reaffirms Guidance - The Globe and Mail
Ardelyx (ARDX) Is Up 6.2% After Revenue Rises And Loss Narrows As New CLO Joins - simplywall.st
Ardelyx | 8-K: Ardelyx Reports First Quarter 2026 Financial Results and Provides Business Update - Moomoo
Ardelyx | 10-Q: Q1 2026 Earnings Report - Moomoo
Ardelyx (NASDAQ:ARDX) Shares Gap Down After Earnings Miss - MarketBeat
Ardelyx, Inc. (NASDAQ:ARDX) Q1 2026 Earnings Call Transcript - Insider Monkey
Ardelyx (ARDX) Q1 2026 Earnings Transcript - AOL.com
Analyst Reiterates Buy on Ardelyx, Citing Tenapanor Momentum and Pipeline Upside with Unchanged $18 Price Target - TipRanks
Earnings Call Summary | Ardelyx(ARDX.US) Q1 2026 Earnings Conference - Moomoo
Ardelyx (NASDAQ:ARDX) Posts Quarterly Earnings Results, Misses Expectations By $0.03 EPS - MarketBeat
MSN Money - MSN
Ardelyx, Inc. Q1 2026 Earnings Call Summary - Yahoo Finance
Ardelyx (ARDX) Reports Strong Q1 Revenue and Strategic Developme - GuruFocus
ARDX: Q1 revenue up 38% year-over-year, driven by IBSRELA and XPHOZAH growth, with guidance reaffirmed - TradingView
Ardelyx (ARDX) Reports Q1 Loss, Beats Revenue Estimates - Yahoo Finance
Ardelyx (ARDX) Reports Mixed Q1 Earnings with Revenue Beat - GuruFocus
Ardelyx Q1 Earnings Call Highlights - Yahoo Finance
Compared to Estimates, Ardelyx (ARDX) Q1 Earnings: A Look at Key Metrics - Yahoo Finance
ARDX: Q1 2026 delivered robust 38% revenue growth, driven by IBSRELA and XPHOZAH performance - TradingView
Is Ardelyx (ARDX) Undervalued After Q1 2026? GAAP EPS -$0.15 Mis - GuruFocus
Earnings call transcript: Ardelyx Q1 2026 misses forecasts but shows growth - Investing.com India
Earnings Flash (ARDX) Ardelyx Posts Q1 EPS -$0.15, vs. FactSet Est of -$0.14 - marketscreener.com
Ardelyx Inc (NASDAQ:ARDX) Reports Strong Q1 Revenue Beat as IBSRELA Momentum Accelerates - ChartMill
ARDELYX ($ARDX) Releases Q1 2026 Earnings - Quiver Quantitative
Earnings Flash (ARDX) Ardelyx, Inc. Reports Q1 Revenue $94.5M - marketscreener.com
Ardelyx: Q1 Earnings Snapshot - Barchart
Ardelyx Reports First Quarter 2026 Financial Results and Provides Business Update - The Manila Times
Ardelyx says IBSRELA sales hit $70.1M as it funds new trials - Stock Titan
ARDELYX, INC. 1Q 2026: Revenue $94.5M, EPS $(0.15) — 10-Q Summary - TradingView
Ardelyx (NASDAQ: ARDX) grows Q1 2026 sales but remains unprofitable - Stock Titan
Ardelyx, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2026 - marketscreener.com
Fast-growing Ardelyx (NASDAQ: ARDX) lifts Q1 revenue and reiterates strong 2026 guidance - Stock Titan
Ardelyx 1Q Loss/Shr 15c >ARDX - Moomoo
Ardelyx Target of Unusually Large Options Trading (NASDAQ:ARDX) - MarketBeat
Ardelyx earnings on deck: Can IBSRELA growth offset losses? By Investing.com - Investing.com Nigeria
Ardelyx earnings on deck: Can IBSRELA growth offset losses? - Investing.com UK
Ardelyx Inc (ARDX) Q1 2026 Earnings Call Highlights: Strong Revenue Growth and Strategic Investments By GuruFocus - Investing.com Canada
Ardelyx gains after insider purchase, LPGA marketing deal - MSN
New equity plan shares and pay votes at Ardelyx (NASDAQ: ARDX) 2026 meeting - Stock Titan
ARDX Q1'26 Earnings: EPS estimate is (0.14) USD - TradingView
Millennium entities report 7.4% stake in Ardelyx (NASDAQ: ARDX) - Stock Titan
Ardelyx Inc Stock (ARDX) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.14%
0.48%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):